Carbazochrome-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemECarbazochromeCat. No.: HY-B1587CAS No.: 69-81-8分式: CHNO分量: 236.23作靶點: Others作通路: Others儲存式: Powder -20C 3 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 H2O : 5 mg/mL (21.17 mM; ultrasonic and adjust pH to 12 with NaOH)DMSO

2、: 1 mg/mL (insoluble or slightly soluble)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 4.2332 mL 21.1658 mL 42.3316 mL5 mM 0.8466 mL 4.2332 mL 8.4663 mL10 mM 0.4233 mL 2.1166 mL 4.2332 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Carbazochrome種細(xì)管穩(wěn)定劑，于出的研究。Carbazochrome種抗

3、出劑 1。體外研究 Carbazochrome (0.1-10 M) inhibits the Bradykinin induced and thrombin-induced formation of 3HIP3 in aconcentration-dependent manner 1.Carbazochrome (0.1-1 M), when included from 30 min beforestimulation, significantly suppressed the enhancement of permeability induced by vasoactive substan

4、ces 1.體內(nèi)研究Carbazochrome inhibits the severe pulmonary dysfunction induced by the intravenous injection of1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEradiographic contrast media. Carbazochrome (1-10 mg/kg, i.v.) attenuates pulmonary dysfunction induced bya radiographic contrast medium in rats 2.

5、Animal Model: Male Sprague-Dawley rats weighing 180-230 g 2Dosage: 10 mg/kgAdministration: I.v.; injected 30, 60, or 90 min before Ioxaglate injection (4 g I/kg, i.v.).Result: Attenuated the Ioxaglate-increased vascular permeability at the dose of 1, 5 and 10mg/kg in a dose-dependent manner, achievi

6、ng statistical significance at 5 and 10 mg/kg.REFERENCES1. Toshiaki Sendo, et al. Carbazochrome sodium sulfonate (AC-17) reverses endothelial barrier dysfunction through inhibition ofphosphatidylinositol hydrolysis in cultured porcine endothelial cells. Naunyn Schmiedebergs Arch Pharmacol. 2003 Sep;368(3):175-80.2. Toshiaki Sendo, et al. Carbazochrome attenuates pulmonary dysfunction induced by a radiographic contrast medium in rats. Eur JPharmacol. 2002 Aug 23;450(2):203-8.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use onl